Your institute does not have access to this article
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:23–33.
Thompson PA, Tam CS, O’Brien SM, Wierda WG, Stingo F, Plunkett W, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127:303–9.
Roberts AW, Ma S, Kipps TJ, Coutre SE, Davids MS, Eichhorst B, et al. Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables. Blood. 2019;134:111–22.
Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369:32–42.
Maddocks KFJ, Adritsos L, Awan F, Woyach JA, Grever MR, Stefanos M, et al. editors. A Phase II study of the BTK inhibitor ibrutinib in genetic risk-stratified relapsed and refractory patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Milan, Italy: European Hematology Association Annual Meeting; 2014.
Byrd JC, Brown JR, O’Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213–23.
Jaglowski SM, Jones JA, Nagar V, Flynn JM, Andritsos LA, Maddocks KJ, et al. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. Blood. 2015;126:842–50.
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745–60.
Ahn IE, Tian X, Ipe D, Cheng M, Albitar M, Tsao LC, et al. Prediction of outcome in patients with chronic lymphocytic leukemia treated with ibrutinib: development and validation of a four-factor prognostic model. J Clin Oncol. 2021;39:576–85.
Baliakas P, Jeromin S, Iskas M, Puiggros A, Plevova K, Nguyen-Khac F, et al. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood. 2019;133:1205–16.
Kittai AS, Miller C, Goldstein D, Huang Y, Abruzzo LV, Beckwith K, et al. The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib. Blood. 2021;138:2372–82.
Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, et al. BTK(C481S)-mediated resistance to ibrutinib in chronic lymphocytic leukemia. J Clin Oncol. 2017;35:1437–43.
Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015;1:80–7.
Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood. 2014;123:1810–7.
Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M, et al. Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood. 2015;125:2497–506.
The study is funded in part through R01CA177292, R35CA197734, the D Warren Brown Foundation, and Pelotonia. JAW and KAR are Scholars of the Leukemia and Lymphoma Society.
KM has consulted with Acerta, AstraZeneca, Pharmacyclics, Beigene, Loxo, Lilly, Genentech, Morphosys, Celgene, BMS, Kite. KAR received research funding from Genentech, AbbVie, and Janssen, consulted for Acerta Pharma, AstraZeneca, Innate Pharma, AbbVie, Genentech, Pharmacyclics, and Beigene, and received travel funding from AstraZeneca. SJ has consulted for Kite, Novartis, Juno, Takeda, CRISPR Therapeutics and has received research funding from Kite, Novartis, Juno, Caribou. ASK has consulted for Abbvie, Beigene, Bristol-Myers Squibb, and Janssen. MRG has received consult funding from Pharmacyclics, Astra Zeneca, Ascerta and Axio. JCB has consulted with Acerta, AstraZeneca, Pharmacyclics, Astellas, Syndax, and Jazz Pharmaceuticals and has stock ownership in Vincerx Pharmaceutics. JAW has consulted with Abbvie, AstraZeneca, Beigene, Janssen, Pharmacyclics, Loxo, and Newave, receives research funding from Morphosys, Karyopharm, Pharmacyclics, Janssen, and Schrodinger.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Sigmund, A.M., Huang, Y., Ruppert, A.S. et al. Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib. Leukemia 36, 2129–2131 (2022). https://doi.org/10.1038/s41375-022-01640-y